Trial Profile
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Apalutamide (Primary) ; Gonadotropin releasing hormone
- Indications Adenocarcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms TITAN
- Sponsors Aragon Pharmaceuticals; Janssen Research & Development; Janssen-Cilag
- 27 Jan 2024 Results assessing the OS medians for APA and PBO arms beyond the TITAN follow-up, presented at the 2024 Genitourinary Cancers Symposium
- 02 Jan 2024 Planned End Date changed from 1 Sep 2024 to 5 Sep 2024.
- 05 Dec 2023 Planned End Date changed from 31 May 2024 to 1 Sep 2024.